

# Infosys

2788.05 (Current Price) → 2450.98 (ViVeKam's Fair Price)

18-Jan-2013

## Snap Shot

		High	low
<b>Beta</b>	<b>0.51</b>	<b>Expected Levels (based on the results for 201212)</b>	<b>2941.18</b>
<b>P/E (ttm)</b>	<b>13.91 (Nifty 18.58)</b>		<b>1960.79</b>
<b>EPS (ttm)</b>	<b>166.66 (Nifty 314.25)</b>	<b>MarketCapital</b>	<b>160100.98</b>

## ViVeKam's Snap Shot View

ViVeKam recognizes that, Infosys is **in growth trajectory** for the current quarter based on the analysis performed by us on the Trailing 12 Month (TTM) data, which enables us to understand its performance and pricing. ViVeKam's Expected Value for Infosys for the current quarter is **2450.98**, and hence in relation to the company's market price it is currently **Over Priced** in our assessment. Our past research on this company has found that we have been able to predict the prices with a accuracy of **98.04 %**.


## Expected Vs Actual

Based on ViVeKam's analysis of the TTM performance of the company, an Expected value of 2450.98 has been given for the current quarter. Standard deviation calculated from the latest three months price data is then used to set the possible high and low prices for the current quarter until next quarter results are announced. All these levels are suitably adjusted with Beta values, wherever applicable, to incorporate impact of the market on this share. Accuracy is measured based on the number of times prices fell within high and low values.

ViVeKam's expected High and Low Values **adjusted with the company's Beta**, for the latest trailing six quarters.




Actual Prices plotted against ViVeKam's expected high and low values for the latest trailing six quarters.



**ViVeKam's predictions of future High and Low values.**

ViVeKam expects the prices for Infosys to range between a high of **2941.18** and a low of **1960.79** for the current quarter. Please note that these are adjusted with the company's beta value, which when taken into consideration improves the companies accuracy to a great extent. Daily beta adjusted values are supplied by ViVeKam to its registered clients.



**Stock Health**

From the current levels, Vivekam predicts this company may not grow further. ViVeKam's scope to grow parameter compares the current market price to the expected value, thereby indicating the percentage the stock is likely to grow, if any. So the higher the percentage, better the stock.

**Quarterly Earnings Comparison**

Details	201112	201203	201206	201209	201212	Scope to Grow
EPS	129.58	147.50	157.08	166.13	166.66	Expensive
Price(at End of Quarter)	2767.65	2866.30	2509.20	2534.95	2318.70	
P/E	21.36	19.43	15.97	15.26	13.91	
Nifty EPS	281.52	283.26	299.71	298.37	314.25	
Nifty Price(at End of Quarter)	4624.30	5295.55	5278.90	5703.30	5905.10	
Nifty P/E	16.43	18.70	17.61	19.11	18.58	

How does Infosys perform in latest TTM when compared with Nifty? Pay attention to the factors marked 'Watch' in the remarks column.

### Company v/s Index

P&L Items(Per Share)	Your Portfolio		Nifty	Remarks
	INR	As %	As %	
Net Sales / Service Revenue	668	100	100	
Cost of Production / Service	427	63.96	78.72	
Operating Profit	241	36.04	21.28	
Interest	0	0	1.30	
Depreciation	16	2.36	2.64	
Income Tax	58	8.73	4.60	
Profit After Tax	167	24.96	12.74	
Cash Profit Generated	182	27.31	15.38	
Price to Earnings (P/E)	16.73		19.11	
Market Value Today	2,788		6,064.40	
Beta Value	0.51			Too Defensive
Business Value of Portfolio	1,851			
Market / Business Value	1.51		1.36	

If you are convinced with the logic and authenticity it carries, and you wish to use ViVeKam's Alert / Execution service, please write to [sales@vivekam.co.in](mailto:sales@vivekam.co.in) to sign up. Our clients enjoy the right to receive alerts as and when their select stocks / portfolios reach our expected High/Low values. Upon the clients request, order will also be auto generated and placed with their brokers.

#### Disclaimer:

ViVeKam uses data procured from reliable sources for it's decision making on any given company at all points of time. Though every care has been taken to have clean and reliable data for our decision making process, it is possible that the data relied upon by ViVeKam may have inaccuracies or inconsistencies in it. Consequently, some of the decisions may be different than communicated, if the accurate data were available. Users of reports / opinions / advises are cautioned to apply due care before acting upon them, in their own interest.